To the Moon? What is going on with JAZZ?

This afternoon we watched Jazz Pharmaceuticals rise 6.3% to a price of $113.02 per share. The Mid-Cap Pharmaceutical company is now trading -37.41% below its average target price of $180.56. Analysts have set target prices ranging from $117.0 to $230.0 per share for Jazz Pharmaceuticals, and have given the stock an average rating of buy.

The stock has an average amount of shares sold short at 6.8%, and a short ratio of 5.13. Since 2.78% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 97.1% of Jazz Pharmaceuticals's shares being owned by this investor type.

Institutions Invested in Jazz Pharmaceuticals

Date Reported Holder Percentage Shares Value
2024-03-31 Blackrock Inc. 11% 7,069,920 $799,042,334
2024-03-31 Vanguard Group Inc 10% 6,448,689 $728,830,809
2024-03-31 State Street Corporation 4% 2,462,135 $278,270,489
2024-03-31 Lsv Asset Management 4% 2,380,858 $269,084,563
2024-03-31 JP Morgan Chase & Company 2% 1,494,538 $168,912,679
2024-03-31 Polaris Capital Management Inc 2% 1,432,660 $161,919,228
2024-03-31 Capital World Investors 2% 1,427,860 $161,376,732
2024-03-31 Ameriprise Financial, Inc. 2% 1,368,949 $154,718,611
2024-03-31 Pacer Advisors, Inc. 2% 1,293,726 $146,216,908
2024-03-31 Renaissance Technologies, LLC 2% 1,165,568 $131,732,491

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Jazz Pharmaceuticals.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.